{"id":5778,"date":"2024-09-16T09:45:59","date_gmt":"2024-09-16T14:45:59","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5778"},"modified":"2025-06-27T11:11:21","modified_gmt":"2025-06-27T16:11:21","slug":"nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en el Euretina Innovation Spotlight y el Ophthalmology Futures Forum en Barcelona"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5778\" class=\"elementor elementor-5778\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-50949d8c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"50949d8c\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4a8f31fb\" data-id=\"4a8f31fb\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a361ec7 elementor-widget elementor-widget-text-editor\" data-id=\"a361ec7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>DALLAS, 16 de septiembre de 2024 \u2014 Nanoscope Therapeutics Inc., una empresa de biotecnolog\u00eda en fase cl\u00ednica que desarrolla terapias g\u00e9nicas para enfermedades retinianas hereditarias y atrofia geogr\u00e1fica, anunci\u00f3 hoy sus presentaciones en el Euretina Innovation Spotlight y en el Ophthalmology Futures Forum, que tendr\u00e1n lugar el 18 de septiembre en Barcelona, Espa\u00f1a. Los detalles de las presentaciones son los siguientes:<\/p><p><b>T\u00edtulo:<\/b>\u00a0Avances en la restauraci\u00f3n de la visi\u00f3n: optogen\u00e9tica independiente de mutaciones para enfermedades hereditarias de la retina y atrofias geogr\u00e1ficas<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>DMAE no neovascular y enfermedades renales cr\u00f3nicas<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">18 de septiembre de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">14:35 h CEST<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b><a href=\"https:\/\/ccib.es\/en\/\" target=\"_blank\" rel=\"nofollow noopener\">Centro de Convenciones Internacional de Barcelona<\/a><br class=\"dnr\" \/><b>Presentador:\u00a0<\/b>Samuel Barone, MD, director m\u00e9dico<\/p><p>En su presentaci\u00f3n, seguida de un panel de discusi\u00f3n, el Dr. Barone destacar\u00e1 las l\u00edneas de tratamiento con opsina multicaracter\u00edstica (MCO) de Nanoscope para el tratamiento de la p\u00e9rdida grave de la visi\u00f3n debido a la retinitis pigmentosa, la degeneraci\u00f3n macular de Stargardt y la atrofia geogr\u00e1fica.<\/p><p><b>T\u00edtulo:<\/b>\u00a0Democratizaci\u00f3n de la terapia g\u00e9nica para enfermedades degenerativas de la retina<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Presentaciones de la empresa 3<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:<\/b>\u00a0<span class=\"xn-chron\">18 de septiembre de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:<\/b>\u00a017:55 h CEST<br class=\"dnr\" \/><b>Ubicaci\u00f3n:<\/b>\u00a0<a href=\"https:\/\/www.esferic.es\/\" target=\"_blank\" rel=\"nofollow noopener\">Esferic Barcelona<\/a><br class=\"dnr\" \/><b>Presentador:<\/b>\u00a0Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico<\/p><p>Durante su presentaci\u00f3n, el Dr. Mohanty destacar\u00e1 la terapia g\u00e9nica optogen\u00e9tica agn\u00f3stica de mutaciones para la restauraci\u00f3n de la visi\u00f3n en distrofias retinianas hereditarias y atrofia geogr\u00e1fica. Tambi\u00e9n participar\u00e1 en una mesa redonda presidida por el Prof.\u00a0<span class=\"xn-person\">Dominik Fischer<\/span>, Profesor de la\u00a0<span class=\"xn-org\">Universidad de Oxford<\/span>.<\/p><p><b>T\u00edtulo del panel:<\/b>\u00a0Perspectivas de la terapia g\u00e9nica y celular para las enfermedades de la parte posterior del ojo: \u00bfEs esto realmente un negocio?<br class=\"dnr\" \/><b>Fecha del panel:<\/b>\u00a0<span class=\"xn-chron\">18 de septiembre de 2024<\/span><br class=\"dnr\" \/><b>Hora del panel:<\/b>\u00a018:40 \u2013\u00a0<span class=\"xn-chron\">19:10 h CEST<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:<\/b>\u00a0<a href=\"https:\/\/www.esferic.es\/\" target=\"_blank\" rel=\"nofollow noopener\">Esferic Barcelona<\/a><br class=\"dnr\" \/><b>Miembro del jurado:<\/b>\u00a0Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico<\/p><p>Ambos eventos incluyen oportunidades de establecer contactos con l\u00edderes de la industria, m\u00e9dicos, innovadores, reguladores e inversores. El equipo de gesti\u00f3n estar\u00e1 presente en estos eventos y podr\u00e1 asistir a reuniones.<\/p><p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades degenerativas de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La empresa tambi\u00e9n ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p><p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS Sept. 16, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentations at the\u00a0Euretina Innovation Spotlight\u00a0and at\u00a0Ophthalmology Futures Forum\u00a0taking place on 18th September in\u00a0Barcelona, Spain. Details for the presentations are as follows: Title:\u00a0Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5782,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-16T14:45:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:11:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona\",\"datePublished\":\"2024-09-16T14:45:59+00:00\",\"dateModified\":\"2025-06-27T16:11:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/\"},\"wordCount\":392,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_EIS_LI_2024._V1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_EIS_LI_2024._V1.jpg\",\"datePublished\":\"2024-09-16T14:45:59+00:00\",\"dateModified\":\"2025-06-27T16:11:21+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_EIS_LI_2024._V1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_EIS_LI_2024._V1.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/16\\\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en Euretina Innovation Spotlight y Ophthalmology Futures Forum en Barcelona - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-16T14:45:59+00:00","article_modified_time":"2025-06-27T16:11:21+00:00","og_image":[{"width":2000,"height":2000,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona","datePublished":"2024-09-16T14:45:59+00:00","dateModified":"2025-06-27T16:11:21+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/"},"wordCount":392,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/","name":"Nanoscope Therapeutics anuncia presentaciones en Euretina Innovation Spotlight y Ophthalmology Futures Forum en Barcelona - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg","datePublished":"2024-09-16T14:45:59+00:00","dateModified":"2025-06-27T16:11:21+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_EIS_LI_2024._V1.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/16\/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5778"}],"version-history":[{"count":8,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5778\/revisions"}],"predecessor-version":[{"id":9036,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5778\/revisions\/9036"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5782"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}